Please login to the form below

Not currently logged in
Email:
Password:

Lilly partners with Wal-Mart

Eli Lilly has partnered with retailer Wal-Mart to sell an affordable version of the pharma company's Humulin synthetic human insulin product for diabetes

Eli Lilly has partnered with Wal-Mart, the country's largest retailer, to sell an affordable version of the pharma company's Humulin synthetic human insulin product for diabetes in nationwide Wal-Mart pharmacies. The deal represents the first time that Lilly has partnered with a retail pharmacy on a co-branded product.

The product, which will be available to consumers starting in mid-September, will be sold under the dual-branded name Humulin ReliOn.

Wal-Mart, which has more than 4,300 US stores, already offers a number of $9 diabetes management products under the ReliOn brand, including the ReliOn Ultima Blood Glucose Meter, ReliOn Ultima Blood Glucose Test Strips, and the ReliOn A1c test.

Lilly's Humulin generated worldwide sales of $1bn last year, but is being overshadowed by an even bigger moneymaker, the company's newer Humalog insulin, which brought in $2bn during the same period.

23rd June 2010

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

dementia
Alzheimer’s Research UK highlights socio-economic inequalities in dementia risk
The charity aims to improve the number of women participating in dementia research and grow awareness of dementia risk factors...
Data security
Concerns about data security are building a strong case for clinical mobility in EMEA
Electronic medical records have transformed the storage of sensitive information but how can the healthcare sector continue to protect patient and staff data?...
Mainimage2
The role of digital health technology tools in supporting medical adherence
How DHT-based digital interventions can help to support patients and improve adherence...